08 Nov, EOD - Indian

SENSEX 79486.32 (-0.07)

Nifty 50 24148.2 (-0.21)

Nifty Bank 51561.2 (-0.68)

Nifty IT 42050.15 (0.71)

Nifty Midcap 100 56352 (-1.33)

Nifty Next 50 69774.2 (-1.23)

Nifty Pharma 22542.25 (0.07)

Nifty Smallcap 100 18445.6 (-1.70)

08 Nov, EOD - Global

NIKKEI 225 39500.37 (0.30)

HANG SENG 20728.19 (-1.07)

S&P 6005.57 (0.46)

Login/Signup
LOGIN HERE
Cancel

Astrazeneca Pharma India Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 506820 | NSE Symbol : ASTRAZEN | ISIN : INE203A01020 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
24-Jul-2024 08-Aug-2024 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter ended June 30 2024. We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2024 to August 10 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Please find the enclosed financial results for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 08/08/2024)
15-May-2024 27-May-2024 Dividend ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve 1. The Audited financial results of the Company for the quarter and year ended March 31 2024. 2. To recommend Dividend if any on the equity shares of the Company for the financial year 2023-24. We also inform you that the Trading Window remains closed for all Designated Persons from March 16 2024 to May 29 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. We wish to inform that at the meeting of Board of Directors of the Company held on May 27, 2024, the Board has recommended dividend of Rs. 24/- per equity share of Rs. 2/- each subject to the approval of the shareholders at the forthcoming AGM of the Company. (As Per BSE Announcement Dated on 27/05/2024)
25-Jan-2024 08-Feb-2024 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31 2023. We would also like to inform you that the Trading Window remains closed for all Designated Persons from December 16 2023 to February 10 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. Please find enclosed copy of the Financial Results for the quarter ended December 31, 2023. (As Per BSE Announcement Dated on 08/02/2024)
30-Oct-2023 09-Nov-2023 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023. We would also like to inform you that the Trading Window remains closed for all Designated Persons from September 16 2023 to November 11 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board Meeting of the Company held on Thursday, November 9, 2023, the Board of Directors considered and approved the Unaudited Financial Results for the quarter ended September 30, 2023. (As per BSE Announcement Dated on 09/11/2023)
04-Aug-2023 14-Aug-2023 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2023. We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2023 to August 16 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 14, 2023 are enclosed herewith. The Board Meeting started at 10:30 a.m and concluded at 1:30 p.m. At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 14, 2023 are enclosed herewith. The Board Meeting started at 10:30 am and concluded at 1:30 pm. (As Per BSE Announcement Dated on 14.08.2023)
22-May-2023 30-May-2023 Accounts ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve 1. The Audited Financial Results of the Company for the quarter and year ended March 31 2023; and 2. To recommend Dividend if any on the Equity Shares of the Company for the Financial Year 2022-23. The Board of Directors of the Company at its Meeting held today i.e., May 30, 2023, inter alia, recommended Dividend of Rs. 16/- per equity share for the Financial Year 2022-23 This is to inform that the Board of Directors at its Meeting held today i.e., May 30, 2023 noted the retirement of Mr. Rajesh Marwaha (DIN: 01458768) from the Office of Chief Financial Officer and Whole-time Director of the Company with effect from the closing of business hours on September 30, 2023. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company. The Board of Directors of the Company at its Meeting held today i.e., May 30, 2023, has inter-alia: 1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2023. The said Audited Financial Results together with the Audit report of the Statutory Auditors dated May 30, 2023 are enclosed herewith. 2. Recommended Dividend of Rs. 16/- per equity share for the Financial Year 2022-23. We also confirm that the Statutory Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the Financial Year ended March 31, 2023. The Board Meeting concluded at 4:30 p.m. Please take the same on record. (As Per BSE Announcement Dated on 30.05.2023)
30-Jan-2023 10-Feb-2023 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve This is to inform that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Friday February 10 2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2022. We would also like to inform you that the Trading Window remains closed for all Designated Persons from December 16 2022 to February 12 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 inter alia considered and approved the Unaudited Financial Results for the quarter ended December 31, 2022 based on the recommendation of the Audit Committee. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors dated February 10, 2023 are enclosed herewith. The Meeting commenced at 2:30 P.M. and concluded at 5.00 P.M. (IST). (As Per BSE Announcement dated on 10.02.2023)
14-Dec-2022 14-Dec-2022 Change in Directors This is to inform that the Board of Directors at its Meeting held today i.e., December 14, 2022, considered and transacted inter alia the following business: 1. Noted the Resignation of Mr. Gagandeep Singh Bedi (DIN: 07844333) from the Office of Managing Director and also as Director of the Company with effect from the closing of business hours on December 31, 2022. The details of the resignation are enclosed below as 'Annexure- A'. 2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Sanjeev Panchal (DIN: 09823879), as Additional Director and also as Managing Director of the Company for a period of three (3) years with effect from January 1, 2023 subject to the approvals of the Members of the Company through Postal Ballot and Central Government, if so needed. Brief details of Mr. Sanjeev Panchal are enclosed below as 'Annexure- B'.
31-Oct-2022 11-Nov-2022 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve This is to inform you that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Friday November 11 2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2022. We would also like to inform you that the Trading Window remains closed for all Designated Persons from September 16 2022 to November 13 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Please find the enclosed file relating to the captioned subject for your reference. The Meeting commenced at 1:30 P.M. and concluded at 3:30 P.M.(IST). Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the re-appointment of Mr. Rajesh Marwaha (DIN: 01458768), Chief Financial Officer and Director of the Company as Whole-time Director for a further period of three (3) years with effect from December 2, 2022 subject to the approval of the Members of the Company through Postal Ballot. Brief details of Mr. Rajesh Marwaha are enclosed below as 'Annexure- A'. Kindly take the above on your records. (As Per BSE Announcement dated on 11.11.2022)
01-Aug-2022 08-Aug-2022 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Monday August 8 2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2022. We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2022 to August 10 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board meeting of the Company held on Monday, August 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 8, 2022 are enclosed herewith. (As Per BSE Announcement Dated on 08/08/2022)
18-May-2022 26-May-2022 Accounts Final Dividend & Audited Results AstraZeneca Pharma India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2022, inter alia: 1. To consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022. 2. To recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022. Further, the 'Trading Window' remains closed for all Designated Persons, from March 16, 2022 to May 28, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. (As per BSE Announcement Dated on 19/5/2022) AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2022, inter alia, has recommended Final Dividend of Rs. 8/- per equity share for the financial year 2021-22. (As Per BSE Announcement Dated on 26.05.2022) We would wish to inform that at the Meeting of the Board of Directors of the Company held on May 26, 2022, the Board have recommended a Final Dividend of Rs. 8/- per equity share of Rs. 2/- each, subject to the approval of shareholders at the forthcoming Annual General Meeting of the Company. The dividend, if approved, by the shareholders, will be credited/dispatched within 30 days from the date of Annual General Meeting of the Company. (As per BSE Announcement Dated on 27/5/2022)
01-Feb-2022 08-Feb-2022 Quarterly Results Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, February 8, 2022 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2021 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2021 to February 11, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board meeting of the Company held on Tuesday, February 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 8, 2022 are enclosed herewith. (As per BSE Announcement Dated on 08/02/2022)
02-Nov-2021 09-Nov-2021 Quarterly Results Quarterly Results At the Board meeting of the Company held on Tuesday, November 9, 2021 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 9, 2021 are enclosed herewith. (As Per BSE Announcement dated on 09.11.2021)
02-Aug-2021 09-Aug-2021 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2021 ,inter alia, to consider and approve i. the Unaudited Financial Results of the Company for the quarter ended June 30, 2021 ii. declaration of an Interim Dividend, if any, to the equity shareholders of the Company for the financial year 2021-22 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from June 16, 2021 to August 11, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 09 2021 inter alia has declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22 AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 09 2021 inter alia has declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22. We would wish to inform that at the Meeting of the Board of Directors of the Company held today i.e., on August 9, 2021, the Board have inter-alia declared an Interim Dividend of Rs. 2 per equity share. The Board of Directors have fixed August 20, 2021 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend. The Interim Dividend shall be paid/dispatched to the shareholders on or before September 7, 2021. The Board of Directors of the Company at their meeting held today i.e, August 9, 2021, has inter-alia: 1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 9, 2021 are enclosed herewith. 2. Declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22 3. Fixed August 20, 2021 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend (As Per BSE Announcement Dated on 8/9/2021) AstraZeneca Pharma India Ltd has informed BSE that the Company has fixed August 20, 2021 as the Record Date for the purpose of Payment of Interim Dividend. (As Per BSE Announcement dated on 10.08.2021)
18-May-2021 25-May-2021 Accounts ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, May 25, 2021 inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from March 16, 2021 to May 27, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board meeting of the Company held on Tuesday, May 25, 2021 the Board of Directors considered and approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The said Audited Financial Results together with the Audit report of the Statutory Auditors dated May 25, 2021 are enclosed herewith. We also confirm that the Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2021. The Board meeting concluded at 4.05 p.m (As Per BSE Announcement dated on 25.05.2021) The Board of Directors of the Company at their meeting held on May 25, 2021, have, inter alia, approved the re-appointment of Ms. Revathy Ashok (DIN 00057539) as an Independent Director of the Company for a second term of 5 years with effect from December 2, 2021, subject to approval of shareholders of the Company at the ensuing 42nd Annual General Meeting. Further, in compliance with circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE respectively, we affirm that Ms. Revathy Ashok is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Ms. Revathy Ashok is not related to any other director of the Company. A brief profile of Ms. Revathy Ashok is enclosed. The Board of Directors of the Company at their meeting held on May 25, 2021, have, inter alia, approved the Re-appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP (ICAI Firm Registration No.304026E/E-300009), as the Statutory Auditors of the Company for a second term of five (5) years, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM), to hold office from the conclusion of 42nd AGM till the conclusion of 47th AGM. The Company has received the certificate of eligibility in accordance with Sections 139, 141 and other applicable provisions, if any of the Companies Act, 2013 read with the Rules issued thereunder, from M/s. Price Waterhouse & Co. Chartered Accountants LLP. (As per BSE Announcement Dated on 26/05/2021)
1 2